Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics

Roche (OTC-PINK:RHHBY) has expanded its collaboration with Janssen Biotech to enhance the development of companion diagnostics aimed at personalised healthcare.

Rhea-AI Summary

Roche (OTC-PINK:RHHBY) has expanded its collaboration with Janssen Biotech to enhance the development of companion diagnostics aimed at personalised healthcare. This new agreement, announced on February 9, 2023, will include a diverse range of technologies such as blood and tissue biomarkers, digital pathology, and next-generation sequencing. The collaboration aims to improve access to targeted treatment options for patients, exemplifying Roche's commitment to precision medicine. Successful projects may include new immunohistochemistry assays and advanced data analysis for patient identification.

Positive

• Expansion of collaboration with Janssen enhances Roche's position in the companion diagnostics market.
• Broader range of technologies implemented for personalized healthcare solutions.
• Potential development of new assays and data analysis techniques could improve patient identification.

Negative

• None.

Argus Session date unavailable

+1.68% session move Open Argus

Details

News Market Reaction – CHGCY

The recorded move for CHGCY in the trading session of this news was +1.68%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New agreement expands activities to include a wide-range of companion diagnostics, including tissue and blood-based biomarkers, sequencing and digital pathology.
  
  
• Collaboration builds on commitment to personalised healthcare through expanding access of companion diagnostics to enable targeted treatment options for patients.

TUCSON, Ariz., Feb. 9, 2023 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has expanded its collaboration with Janssen Biotech Inc. (Janssen) to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

The new, expanded agreement broadens opportunities for Roche and Janssen to collaborate in the precision medicine field with multiple companion diagnostics technologies, including immunohistochemistry (IHC), digital pathology, next generation sequencing, polymerase chain reaction and immunoassays.

"This is a great example of how Roche is spearheading the next generation of healthcare by working with industry leaders around the globe," said Jill German, Head of Pathology Lab at Roche Diagnostics. "Through collaboration, we aim to help advance personalised healthcare by developing tests that make more targeted therapies available to the patients who need them."

Examples of projects that may develop as a result of this collaboration include exploring data and tissue image analysis and the development of a new IHC assay to support patient identification and enrollment for personalised treatment.

About Roche 
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For further information please contact

Jo Lynn Garing, Roche Diagnostics Communications Mobile: +1 317-363-7286 E-mail: jo_lynn.garing@roche.com

View original content:https://www.prnewswire.com/news-releases/roche-expands-collaboration-with-janssen-to-advance-personalised-healthcare-through-companion-diagnostics-301742757.html

SOURCE Roche

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the significance of Roche's expanded collaboration with Janssen Biotech?

The expanded collaboration aims to enhance the development of companion diagnostics, improving access to targeted treatments and advancing personalized healthcare.

What technologies are included in Roche's new agreement with Janssen?

The new agreement includes a variety of companion diagnostics technologies such as tissue and blood biomarkers, digital pathology, and next-generation sequencing.

When was Roche's collaboration with Janssen announced?

The collaboration was announced on February 9, 2023.

How does Roche's collaboration with Janssen impact personalized healthcare?

The collaboration aims to develop diagnostics that enable more targeted treatment options for patients, thus improving personalized healthcare delivery.

What is Roche's stock symbol?

Roche's stock symbol is OTC-PINK:RHHBY.